| Date | Title | Description |
| 18.09.2025 | America Rises: GSK Pumps $30 Billion into US Pharma | GSK commits $30 billion to US research and manufacturing over five years. This significant investment targets advanced technologies, AI, and next-generation biopharma facilities. It will create numerous high-skilled American jobs. The move ... |
| 17.09.2025 | GSK plots $30bn investment into US in latest blow to UK’s pharma sector | GSK has unveiled a new plan to spend $30bn (£22bn) on research and manufacturing facilities in the US.
The London-based business said the capital would be deployed over the next five years and would create hundreds of high-skilled American ... |
| 17.09.2025 | UK’s GSK announces $30 billion U.S. pharma investment amid Trump state visit | GSK’s investment will include $1.2 billion toward advanced manufacturing, AI and advanced digital technologies, the drug maker said.
The investment commitment comes as President Donald Trump is in the U.K. for a three-day state visit.
Major... |
| 30.07.2024 | The New Frontier in Biotech: Partnerships and Innovations Shaping the Future of Medicine | In the ever-evolving landscape of biotechnology, partnerships are the lifeblood of innovation. Two recent collaborations highlight this trend: GSK's partnership with Flagship Pioneering and Autobahn Therapeutics' successful funding round. B... |
| 29.07.2024 | GSK partners with Flagship Pioneering to develop medicines and vaccines | The two companies have agreed to jointly fund up to $150M upfront to identify promising concepts
Flagship Pioneering is a biotechnology company that creates and funds bioplatform companies; since its founded in 2000, it has developed more t... |
| 17.05.2024 | GSK raises £1.25bn as it offloads final stake in Haleon | GSK has offloaded the remainder of its stake in its former consumer goods division Haleon for £1.25bn today, severing the final ties between the two firms following a blockbuster de-merger two years ago.
In an announcement this morning, the... |
| 20.12.2023 | GSK Expands Again in Cancer, Paying Hansoh $185M for Another ADC | GSK’s cancer drug pipeline is getting bigger with the addition of another antibody drug conjugate, or ADC. It’s the second time in as many months that GSK has turned to Hansoh Pharma for one of the China-based biotech’s drugs.
Per deal term... |
| 19.01.2022 | Unilever backs down on raising £50bn bid for GSK consumer health arm | Unilever has ruled out raising its £50bn bid for GlaxoSmithKline’s consumer health arm after the pharma giant rebuffed the latest of three approaches in December. |
| 27.10.2021 | GSK brings Johns Hopkins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO | GlaxoSmithKline CEO Emma Walmsley is adding another scientist to the company’s board. Early Wednesday — alongside their Q3 update — Walmsley put out word that Harry “Hal” Dietz, a professor of genetics and medicine... |
| 13.10.2021 | GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report | The spinout of GlaxoSmithKline’s consumer health unit could reportedly take the form of a $54 billion sale to private equity firms.
It would mark a pivot from previous plans to turn that group into its own listed company ... |
| 20.09.2021 | GSK - ANNOUNCES £50M INVESTMENT IN RENEWABLE ENERGY AND CARBON REDUCTION | GSK - ANNOUNCES £50M INVESTMENT IN RENEWABLE ENERGY AND CARBON REDUCTION |
| 20.09.2021 | GlaxoSmithKline : GSK Announces £50m Investment In Renewable Energy And Carbon Reduction | Sept 20 (Reuters) - GlaxoSmithKline PLC:
* PRESS RELEASE: GSK ANNOUNCES MAJOR RENEWABLE ENERGY INVESTMENT AND LOW CARBON INHALER PROGRAMME ALONGSIDE LIFE SCIENCES SECTOR RACE TO ZERO BREAKTHROUGH AT NYC CLIMATE WEEK
* GSK - ANNOUNCES £50M... |
| 06.08.2021 | A Wharton MBA grad and a former GSK exec’s healthcare startup raises $3 million to reach more PCOS patients | The Mumbai-based startup was founded in August last year.
Shashwata has an MBA from Wharton and studied data science at Yale University.
Shobhita has spent several years working with leading healthcare companies including GlaxoSmithKline. I... |
| 03.12.2018 | Term Sheet — Monday, December 3 | THE CRYSTAL BALL
Good morning, Term Sheet readers. Sending this from a plane, so the deals section is a little abbreviated today.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Send an email to polina.marinova@f... |
| 03.12.2018 | GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billion | Tesaro’s only marketed product is Zejula (niraparib), a PARP inhibitor approved for the maintenance treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer, following a response to treatment with platinum-based chemother... |
| 13.08.2018 | Fresh from GSK deal, Orchard raises $150M for multifront late-phase gene therapy push | Orchard Therapeutics has raised $150 million (€132 million) to advance three gene therapies toward approval. The series C round continues a transformative year for Orchard defined by the acquisition of GlaxoSmithKline’s portfolio of approve... |
| 13.08.2018 | Fresh from hauling in GSK’s budget-priced gene therapy group, Orchard harvests $150M mega-round. Is it time to IPO? | Just a few months ago Orchard Therapeutics was handed the opportunity of taking over GlaxoSmithKline’s gene therapy group, which had pushed the field’s second product, Strimvelis, to the European market — without seein... |
| 27.04.2017 | Tesaro gets its PD-1 registration study started, hunting accelerated OK; Ultragenyx hustles into PhIII | → Tesaro $TSRO has launched a registration study for its PD-1 drug TSR-042, which was developed in a collaboration with AnaptysBio. The biotech — which is gunning for an accelerated approval — is planning to start a serie... |
| 16.11.2016 | GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round | Jason Gardner, Magenta CEO. Jen Randall Photography.
Jason Gardner returned to his old stomping grounds in Cambridge, MA back in the fall of 2014 with a mission to hunt up new collaborations for the pharma giant GlaxoS... |
| 27.10.2016 | GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO | Andrew Witty, GSK
GlaxoSmithKline didn’t just kill losmapimod on Wednesday. The pharma giant was also forced to dump a late-stage HIV drug acquired from Bristol-Myers late last year in a $1.46 billion deal. Here’s the explan... |
| 21.10.2016 | India: Entrepreneur GSK Velu’s eye care chain to raise $30m funding, investors look to exit | Premium
Maxivision Super Specialty Eye Hospitals, a Chennai-based eyecare chain owned by G.S.K. Velu, plans to raise about Rs 200 crore, providing an exit to existing investors, two persons close to the development said. Chennai-based inves... |
| 30.06.2016 | New ovarian cancer drugs raise hope — but not for all | Promising new therapies are springing up to treat ovarian cancer, long one of the most deadly and hard to treat malignancies.
The latest: An experimental drug from Tesaro, a small biotech company based in Waltham, Mass. The company on Wedne... |
| 31.01.2014 | East Coast Biotech Roundup: Dicerna, J&J, Neurophage, & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
[Updated, 8:44 am ET] Local biotechs were out for cash this week. One company saw its share price triple in its first day on the Nasdaq. Three others lined up stock offerings.... |
| 08.08.2013 | GSK launches $50M fund to invest in pioneering bioelectronics technology | It is looking to invest in three different sets of companies:
New start-up companies that aim to pursue the vision of bioelectronic medicines.
Existing companies with technologies that are interacting with the peripheral nervous system thro... |
| 06.03.2013 | Tesaro pockets $91M in big financing as major cancer trials continue | With key results expected from its lead cancer program this year, the cancer drug specialist Tesaro ($TSRO) has stocked its coffers with $91.2 million from a public stock offering. The sale of 5.4 million shares of common stock adds to the ... |
| 28.08.2012 | Rock Health boosts startup funding to $100,000, adds Kleiner Perkins as a partner | In an interview with TechCrunch, Rock Health CEO Halle Tecco said that the increase in funding reflects the fact that healthcare startups often need more money to develop physical prototypes and get U.S. Food and Drug Administration approva... |
| 08.06.2012 | Less than 1% of HGSI shares tendered for sale; GSK extends $2.6B offer | While GSK is trying to secure a sale within this month, HGS has a different timeline in mind. The company had adopted a “poison pill” provision that would dilute GSK’s holdings in the event that the British pharmaceutical giant went forward... |
| 21.06.2011 | TESARO Secures $101M in Series B Financing | TESARO, Inc., a Waltham, Massachusetts-based oncology-focused biopharmaceutical company, has secured $101m in Series B financing.
The round was led by Kleiner Perkins Caufield & Byers, with participation from founding investor New Enter... |
| 26.05.2010 | Tesaro Secures $60M in Start up Funding | TESARO, Inc., a Boston, Massachusetts-based oncology-focused biopharmaceutical company focused on developing and commercializing new therapeutics and supportive care agents, has secured $60m in start-up funding.
The funds will be used to ac... |
| - | GSK gets pneumococcal vaccine contender with $2.1B Affinivax acquisition | Pneumococcal vaccines sales are dominated by Pfizer, and to a lesser extent, Merck, each company stepping up the competition with recent FDA approvals of shots that offer broader protection. GSK wants a bigger piece of this market so it’s c... |
| - | GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billion | British drugmaker GlaxoSmithKline plans to purchase a US-based manufacturer of drugs for cancers, the two companies said.
GSK and Tesaro said Monday that they had reached an agreement under which the London-based pharmaceutical giant will a... |
| - | Rock Health boosts startup funding to $100,000, adds Kleiner Perkins as a partner | Bam! Rock Health investors up seed funding for startups to $100K shar.es/7JiW3
— Rock Health (@Rock_Health) August 28, 2012
In an interview with TechCrunch, Rock Health CEO Halle Tecco said that the increase in funding reflects the fact tha... |
| - | Less than 1% of HGSI shares tendered for sale; GSK extends $2.6B offer | GlaxoSmithKline‘s (NYSE:GSK) $2.6 billion offer to buy Human Genome Sciences (NASDAQ:HGSI) has enticed holders of 474,029 shares of the Maryland biotechnology company to tender their stock for the sale.
The remaining shareholders now have t... |
